Unknown OBSERVATIONAL NCT04624893

A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin

A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin in the Treatment of Patients With Transplantation Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Sponsor: Jiangsu Cancer Institute & Hospital

Conditions Diffuse Large B-Cell Lymphoma (DLBCL)

Interventions Polatuzumab Vedotin-Piiq

Updated 5 times since 2020 Last updated: Nov 10, 2020 Started: Dec 12, 2019 Primary completion: Dec 31, 2020 Completion: Dec 31, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Diffuse Large B-Cell Lymphoma (DLBCL) and is currently ongoing. Jiangsu Cancer Institute & Hospital leads this study, which shows 5 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Dec 2022 — Jul 2024 [monthly]

Unknown Status

Status: Recruiting → Unknown Status
Jan 2021 — Dec 2022 [monthly]

Recruiting
Dec 2020 — Jan 2021 [monthly]

Recruiting

First recorded

Dec 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu Cancer Institute & Hospital

Data source: Jiangsu Cancer Institute & Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nanjing, China